ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹79.4 Cr (+61.1% YoY) and a net loss of ₹7.2 Cr for Q2 FY27.
Mangalam Drugs & Organics Ltd has dispatched physical letters to shareholders without registered emails. These letters provide web-links to access the Annual Report for FY 2025-26.
Mangalam Drugs and Organics appointed Prabhakar Raghunath Zavar as Non-Executive Independent Director for 60 months, effective 15 September 2026. The disclosure covers a board-level appointment with a background profile and no monetary amount.
Mangalam Drugs will hold a board meeting on 5 November 2026 to consider unaudited September 2026 quarter results. The agenda is proposed only, pending the meeting.
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
Mangalam Drugs and Organics Limited reported defaults on bank loan obligations totaling Rs. 15.57 Crore. The defaults involve cash credit accounts at Bank of Maharashtra and Bank of Baroda.